{"nctId":"NCT00510146","briefTitle":"Olanzapine Treatment of Patients With Bipolar I Disorder","startDateStruct":{"date":"2007-08"},"conditions":["Depression, Bipolar"],"count":514,"armGroups":[{"label":"Olanzapine","type":"EXPERIMENTAL","interventionNames":["Drug: Olanzapine"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Olanzapine (open-label treatment period)","type":"EXPERIMENTAL","interventionNames":["Drug: Olanzapine"]}],"interventions":[{"name":"Olanzapine","otherNames":["LY170053","Zyprexa"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Each patient must be reliable, have a level of understanding sufficient to perform all tests and examinations required by the protocol, and must understand the nature of the study and have provided informed consent\n* All female patients must test negative for pregnancy and females of breast-feeding potential must agree not to breastfeed an infant during the study and for 1 month following the last dose of study drug\n* Patients must fulfill the criteria for a major depressive episode according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV-TR) as well as criteria for bipolar I disorder, depressed, as defined in the DSM-IV-TR, based on clinical assessment and confirmed by the structured diagnostic interview, the Mini International Neuropsychiatric Interview (MINI), at study entry\n* Patients must have a current 17-item Hamilton Depression Rating Scale (HAMD-17) score greater than or equal to 18 at Visit 1 and Visit 2\n* Patients must have a current Young Mania Rating Scale (YMRS) total score less than or equal to 8 at Visit 2.\n\nExclusion Criteria:\n\n* Has received treatment within the past 30 days with a drug (not including study drug) that has not received regulatory approval for any indication at the time of study entry\n* Has participated in a clinical trial of another investigational drug, including olanzapine, within 1 month (30 days) before study entry\n* Was previously treated with olanzapine and had bipolar depression considered to be treatment-resistant to olanzapine or to olanzapine in combination with an available selective serotonin reuptake inhibitor (SSRI)\n* Is experiencing (at the time of study entry) a current episode of bipolar depression that is greater than 90 days in duration\n* Has been treatment-resistant to any therapy prescribed for bipolar depression when olanzapine alone or with an SSRI prescribed at an appropriate dose and duration","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"64 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline to Endpoint in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score (Acute Phase)","description":"The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29.36","spread":"5.71"},{"groupId":"OG001","value":"28.69","spread":"6.33"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.26","spread":"9.73"},{"groupId":"OG001","value":"-11.71","spread":"11.09"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Symptomatic Response at Endpoint (Acute Phase)","description":"Response is defined as a reduction (from baseline to endpoint) of 50% or more in the MADRS total score. The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52.5","spread":null},{"groupId":"OG001","value":"43.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Symptomatic Remission At Any Time (Acute Phase)","description":"Percentage of participants with symptomatic remission at any time as defined as a score of less than or equal to 12 in the MADRS total score. The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53.9","spread":null},{"groupId":"OG001","value":"49.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Endpoint in Clinical Global Improvement- Bipolar (CGI-BP) Severity of Illness Scores-Mania, Depression, Overall Bipolar Illness Scores (Acute Phase)","description":"CGI-BP is a measure of illness severity especially adapted for bipolar illness. It allows rating of mania, depression, and overall illness. The score ranges from 1 (normal, not ill) to 7 (very seriously ill).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.07","spread":"0.29"},{"groupId":"OG001","value":"1.11","spread":"0.35"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.43"},{"groupId":"OG001","value":"0.09","spread":"0.59"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.54","spread":"0.73"},{"groupId":"OG001","value":"4.53","spread":"0.73"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.45","spread":"1.26"},{"groupId":"OG001","value":"-1.20","spread":"1.36"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.45","spread":"0.79"},{"groupId":"OG001","value":"4.44","spread":"0.79"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.40","spread":"1.28"},{"groupId":"OG001","value":"-1.08","spread":"1.27"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Recovery (Acute Phase)","description":"Percentage of participants with recovery defined as a value of less than or equal to 12 in the MADRS total score for at least 4 weeks of post-baseline treatment. The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.7","spread":null},{"groupId":"OG001","value":"9.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Endpoint in Young Mania Rating Scale (YMRS) Total Score (Acute Phase)","description":"The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.14","spread":"2.10"},{"groupId":"OG001","value":"1.95","spread":"2.18"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.78","spread":"2.56"},{"groupId":"OG001","value":"0.31","spread":"4.21"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Endpoint in Hamilton Depression Rating Scale-17 (HAMD-17) Total Score (Acute Phase)","description":"The 17-item HAMD measures depression severity. Each item was evaluated and scored using either a 5-point scale (e.g. absent, mild, moderate, severe, very severe) or a 3-point scale (e.g. absent, mild, marked). The total score of HAMD-17 may range from 0 (normal) to 52 (severe).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.62","spread":"3.47"},{"groupId":"OG001","value":"22.35","spread":"3.53"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.44","spread":"7.02"},{"groupId":"OG001","value":"-9.12","spread":"7.99"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Major Depressive Episode at Endpoint on Mini International Neuropsychiatric Interview (MINI), Depressive Episode Module (Acute Phase)","description":"In the MINI Major Depressive Episode module, participants are asked a series of Yes/No questions to determine whether or not they are experiencing a major depressive episode or a major depressive episode with melancholic features.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55.5","spread":null},{"groupId":"OG001","value":"60.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.8","spread":null},{"groupId":"OG001","value":"74.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Current Hypomanic Episode at Endpoint on MINI Manic Episode Module (Acute Phase)","description":"In the MINI Manic Episode module, participants are asked a series of Yes/No questions to determine whether or not they are currently experiencing hypomanic or manic episodes.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":null},{"groupId":"OG001","value":"0.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Psychotic Disorders and Mood Disorders With Psychotic Features at Endpoint on MINI Psychotic Disorders Module (Acute Phase)","description":"In the MINI Psychotic Features Episode module, participants are asked a series of Yes/No questions to determine whether or not they are currently experiencing mood disorder with psychotic features or current psychotic disorders.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.6","spread":null},{"groupId":"OG001","value":"2.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Alcohol Dependence and Abuse at Endpoint on MINI Alcohol Dependence/Abuse Module (Acute Phase)","description":"In the MINI Alcohol Abuse and Dependence Module, participants are asked a series of Yes/No questions to determine whether or not they are currently experiencing symptoms indicating current alcohol dependence or abuse.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":null},{"groupId":"OG001","value":"0.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Non-Alcohol Psychoactive Substance Use Disorder at Endpoint on MINI Substance Dependence/Abuse Module (Acute Phase)","description":"In the MINI Substance Dependence and Abuse Module, participants are asked a series of Yes/No questions to determine whether or not they are currently experiencing symptoms indicating current non-alcohol substance use dependence or abuse.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Emergence of Mania During the Study (Acute Phase)","description":"Emergence of mania is defined as first occurrence of score of \\>=15 in the YMRS total score in the post-baseline period of Acute Phase. The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":null},{"groupId":"OG001","value":"2.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Extra-Pyramidal Symptoms (EPS) At Endpoint As Measured by Drug-Induced Extra-Pyramidal Symptoms Scale (DIEPSS) (Acute Phase)","description":"EPS symptoms measured by DIEPSS are grouped into 4 categories: parkinsonism, akathisia, dystonia, and dyskinesia. Severity is assessed at 5 levels, from level 0 (none, normal) to level 4 (severe). For Parkinsonism, normal baseline is defined as a score not \\>=3 on 1 item nor \\>=2 on 2 items; abnormal endpoint is defined as a score \\>=3 on 1 item or \\>=2 on 2 items, or an increase of 3 on Parkinsonism total. Baseline akathisia, dystonia and dyskinesia is defined as a score \\<2; abnormal endpoint is a score \\>=2 or an increase \\>= 2 from that baseline score.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.7","spread":null},{"groupId":"OG001","value":"1.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":null},{"groupId":"OG001","value":"0.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Endpoint in Blood Pressure (Acute Phase)","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"112.39","spread":"13.25"},{"groupId":"OG001","value":"115.65","spread":"14.39"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.99","spread":"10.83"},{"groupId":"OG001","value":"-0.67","spread":"11.18"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"112.35","spread":"13.42"},{"groupId":"OG001","value":"114.39","spread":"13.67"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.36","spread":"11.10"},{"groupId":"OG001","value":"0.04","spread":"12.16"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74.77","spread":"10.20"},{"groupId":"OG001","value":"76.87","spread":"10.26"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.48","spread":"8.71"},{"groupId":"OG001","value":"-0.14","spread":"8.44"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73.07","spread":"9.93"},{"groupId":"OG001","value":"73.92","spread":"9.86"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.11","spread":"9.37"},{"groupId":"OG001","value":"0.39","spread":"9.08"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.54","spread":"6.51"},{"groupId":"OG001","value":"1.21","spread":"7.67"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.65","spread":"8.20"},{"groupId":"OG001","value":"-0.45","spread":"11.45"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.92","spread":"5.93"},{"groupId":"OG001","value":"2.96","spread":"5.57"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.52","spread":"6.79"},{"groupId":"OG001","value":"-0.47","spread":"6.78"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Endpoint in Weight (Acute Phase)","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.11","spread":"18.11"},{"groupId":"OG001","value":"68.30","spread":"18.73"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.45","spread":"2.82"},{"groupId":"OG001","value":"-0.13","spread":"2.10"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Endpoint in Glucose and Lipids (Cholesterol, Triglycerides, HDL Cholesterol, LDL Cholesterol)","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.11","spread":"0.58"},{"groupId":"OG001","value":"5.12","spread":"0.57"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.10","spread":"0.61"},{"groupId":"OG001","value":"0.02","spread":"0.54"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.83","spread":"1.01"},{"groupId":"OG001","value":"4.81","spread":"1.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.24","spread":"0.76"},{"groupId":"OG001","value":"-0.07","spread":"0.49"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.39","spread":"0.85"},{"groupId":"OG001","value":"1.34","spread":"0.80"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.26","spread":"0.97"},{"groupId":"OG001","value":"0.03","spread":"0.71"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.77","spread":"0.87"},{"groupId":"OG001","value":"2.83","spread":"0.84"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.17","spread":"0.66"},{"groupId":"OG001","value":"-0.09","spread":"0.48"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.43","spread":"0.41"},{"groupId":"OG001","value":"1.36","spread":"0.35"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.03","spread":"0.25"},{"groupId":"OG001","value":"0.02","spread":"0.21"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Endpoint in Albumin (Acute Phase)","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43.07","spread":"3.85"},{"groupId":"OG001","value":"43.47","spread":"3.69"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.81","spread":"2.89"},{"groupId":"OG001","value":"0.03","spread":"3.11"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Endpoint in Alanine Amino Transferase/Serum Glutamate Pyruvate Transaminase (ALT/SGPT), Aspartate Aminotransferase/Serum Glutamic Oxaloacetic Transaminase (AST/SGOT), Gamma Glutamyl Transferase (GGT)","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.68","spread":"16.53"},{"groupId":"OG001","value":"21.18","spread":"13.17"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.34","spread":"26.90"},{"groupId":"OG001","value":"0.00","spread":"13.63"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.61","spread":"8.34"},{"groupId":"OG001","value":"20.25","spread":"6.70"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.31","spread":"15.66"},{"groupId":"OG001","value":"1.26","spread":"11.06"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.87","spread":"36.59"},{"groupId":"OG001","value":"23.63","spread":"23.17"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.36","spread":"22.70"},{"groupId":"OG001","value":"-1.21","spread":"11.67"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Endpoint in Direct Bilirubin, Total Bilirubin, Uric Acid (Acute Phase)","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.45","spread":"1.23"},{"groupId":"OG001","value":"2.40","spread":"1.08"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.21","spread":"1.03"},{"groupId":"OG001","value":"0.12","spread":"1.02"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.74","spread":"5.18"},{"groupId":"OG001","value":"9.42","spread":"4.58"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.68","spread":"4.57"},{"groupId":"OG001","value":"0.47","spread":"4.27"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"307.19","spread":"92.03"},{"groupId":"OG001","value":"314.38","spread":"86.69"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.55","spread":"51.10"},{"groupId":"OG001","value":"-1.86","spread":"50.37"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Endpoint in Erythrocyte Count (Acute Phase)","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.65","spread":"0.51"},{"groupId":"OG001","value":"4.71","spread":"0.52"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.05","spread":"0.27"},{"groupId":"OG001","value":"0.02","spread":"0.27"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Endpoint in Hematocrit (Acute Phase)","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.42","spread":"0.04"},{"groupId":"OG001","value":"0.43","spread":"0.05"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.01","spread":"0.03"},{"groupId":"OG001","value":"0.00","spread":"0.03"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Endpoint in Hemoglobin A1c (Acute Phase)","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.34","spread":"0.37"},{"groupId":"OG001","value":"5.37","spread":"0.37"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.04","spread":"0.26"},{"groupId":"OG001","value":"-0.03","spread":"0.28"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Endpoint in Hemoglobin (Acute Phase)","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.65","spread":"0.99"},{"groupId":"OG001","value":"8.73","spread":"0.97"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.11","spread":"0.50"},{"groupId":"OG001","value":"0.05","spread":"0.50"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Endpoint in Prolactin (Acute Phase)","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.40","spread":"16.89"},{"groupId":"OG001","value":"15.86","spread":"21.54"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.07","spread":"24.00"},{"groupId":"OG001","value":"-1.18","spread":"26.49"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Endpoint in Urinalysis (UA)- Specific Gravity (Acute Phase)","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.02","spread":"0.01"},{"groupId":"OG001","value":"1.02","spread":"0.01"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.00","spread":"0.01"},{"groupId":"OG001","value":"0.00","spread":"0.01"}]}]}]},{"type":"SECONDARY","title":"Change in Electrocardiogram (ECG) From Baseline to Endpoint (Acute Phase)","description":"Time from electrocardiogram Q wave to the end of the T wave corresponding to electrical systole, fixed correction factor (QTcF interval); Bazett-Corrected QT Interval (QTcB interval).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"406.85","spread":"19.53"},{"groupId":"OG001","value":"408.10","spread":"18.72"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.82","spread":"14.21"},{"groupId":"OG001","value":"0.50","spread":"12.27"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"415.79","spread":"20.55"},{"groupId":"OG001","value":"418.42","spread":"19.95"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.58","spread":"18.01"},{"groupId":"OG001","value":"1.21","spread":"16.02"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Endpoint in Heart Rate (Acute Phase)","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69.63","spread":"12.65"},{"groupId":"OG001","value":"70.51","spread":"11.94"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.49","spread":"11.18"},{"groupId":"OG001","value":"0.87","spread":"11.51"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Endpoint in MINI Suicidality Total Scores (Acute Phase)","description":"The MINI module C (MINI-C) is a rating scale for severity of suicidal thoughts and behaviors. The MINI-C is composed of 12 Yes/No questions with variable scores assigned to each question. The scale ranges from 0 to 52 with higher scores indicating a greater presence of suicidal thoughts and/or behaviors.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.09","spread":"3.44"},{"groupId":"OG001","value":"2.40","spread":"3.49"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.42","spread":"3.71"},{"groupId":"OG001","value":"-0.59","spread":"3.44"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Adverse Events (Acute Phase)","description":"Please refer to the Adverse Event overview for details regarding adverse events and serious adverse events.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"238","spread":null},{"groupId":"OG001","value":"88","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Symptomatic Response in Montgomery-Asberg Depression Rating (MADRS) Depression Rating (Open-Label Phase)","description":"The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). Response is defined as a reduction (from baseline to endpoint) of 50% or more in the MADRS total score.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Symptomatic Remission in the MADRS Total Score (Open-Label Phase)","description":"Percentage of participants with symptomatic remission at any time as defined as a score of less than or equal to 12 in the MADRS total score. The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Recovery (Open-Label Phase)","description":"Percentage of participants with recovery defined as a value of less than or equal to 12 in the MADRS total score for at least 4 weeks of post-baseline treatment. The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Endpoint in Young Mania Rating Scale (YMRS) Total Score (Open-Label Phase)","description":"The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.11","spread":"2.87"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.03","spread":"2.55"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Emergence of Mania During the Study (Open-Label Phase)","description":"Emergence of mania is defined as first occurrence of score of \\>=15 in the YMRS total score in the Open-Label Extension. The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Extra-Pyramidal Symptoms (EPS) at Endpoint As Measured by Drug-Induced Extra-Pyramidal Symptoms Scale (DIEPSS) (Open-Label Phase)","description":"EPS symptoms measured by DIEPSS are grouped into 4 categories: parkinsonism, akathisia, dystonia, and dyskinesia. Severity is assessed at 5 levels, from level 0 (none, normal) to level 4 (severe). For Parkinsonism, normal baseline is defined as a score not \\>=3 on 1 item nor \\>=2 on 2 items; abnormal endpoint is defined as a score \\>=3 on 1 item or \\>=2 on 2 items, or an increase of 3 on Parkinsonism total. Baseline akathisia, dystonia and dyskinesia is defined as a score \\<2; abnormal endpoint is a score \\>=2 or an increase \\>= 2 from that baseline score.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Endpoint in Blood Pressure (Open-Label Phase)","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74.98","spread":"10.77"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.15","spread":"8.28"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73.32","spread":"10.73"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.03","spread":"8.68"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"112.06","spread":"14.58"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.96","spread":"10.37"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"112.26","spread":"14.45"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.27","spread":"10.28"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.75","spread":"5.25"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.16","spread":"6.56"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.19","spread":"6.19"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.65","spread":"7.92"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Endpoint in Weight (Open-Label Phase)","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68.31","spread":"18.54"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.27","spread":"4.00"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Endpoint in Albumin and Total Protein (Open-Label Phase)","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42.64","spread":"3.58"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.53","spread":"2.86"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73.24","spread":"4.39"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.56","spread":"3.78"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Endpoint in Alkaline Phosphatase, Creatinine Phosphokinase (CPK), GGT (Open-Label Phase)","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68.58","spread":"19.33"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.37","spread":"12.85"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"107.36","spread":"133.21"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.73","spread":"124.56"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.90","spread":"32.08"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.78","spread":"25.90"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Endpoint in Chloride (Open-Label Phase)","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"103.62","spread":"2.16"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.33","spread":"2.38"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Endpoint in Creatinine (Open-Label Phase)","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67.48","spread":"14.98"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.05","spread":"7.90"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Endpoint in Erythrocyte Count (Open-Label Phase)","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.64","spread":"0.53"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":"0.30"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Endpoint in Hemoglobin (Open-Label Phase)","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.61","spread":"1.01"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.04","spread":"0.51"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Endpoint in Platelet Count (Open-Label Phase)","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"257.96","spread":"64.25"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.56","spread":"49.94"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Endpoint in Prolactin (Open-Label Phase)","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.64","spread":"18.48"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.41","spread":"17.20"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Endpoint in Uric Acid (Open-Label Phase)","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"324.74","spread":"89.39"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.73","spread":"56.80"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Endpoint in Glucose and Lipids (Cholesterol, Triglycerides, HDL Cholesterol, LDL Cholesterol) (Open-Label Phase)","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.20","spread":"0.57"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":"0.63"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.96","spread":"1.08"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.05","spread":"0.70"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.55","spread":"1.06"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.10","spread":"0.97"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.88","spread":"0.91"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":"0.63"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.39","spread":"0.40"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.05","spread":"0.24"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Endpoint in ECG (Open-Label Phase)","description":"Time from electrocardiogram Q wave to the end of the T wave corresponding to electrical systole, fixed correction factor (QTcF interval); Bazett-Corrected QT Interval (QTcB interval).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"410.09","spread":"19.44"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.80","spread":"15.07"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"421.72","spread":"19.61"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.76","spread":"16.69"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Endpoint in Heart Rate (Open-Label Phase)","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71.85","spread":"11.64"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":"10.79"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With High Suicidality at Endpoint (Open-Label Phase)","description":"The MINI module C (MINI-C) is a rating scale for severity of suicidal thoughts and behaviors. The MINI-C is composed of 12 Yes/No questions with variable scores assigned to each question. The scale ranges from 0 to 52 with higher scores indicating a greater presence of suicidal thoughts and/or behaviors. Based upon scores, suicidality is defined as Low (1-8), Medium (9-16), and High (\\>=17).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Adverse Events (Open-Label Phase)","description":"Please refer to the Adverse Event overview for details regarding adverse events and serious adverse events.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"209","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":343},"commonTop":["Weight increased","Somnolence","Increased appetite","Nasopharyngitis","Sedation"]}}}